Viridian Therapeutics vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
Greenwood Village CO YC W20 clinical biotech (NASDAQ: VRDN) with $636.6M cash; veligrotug BLA submission H2 2025 for thyroid eye disease competing with Tepezza; FcRn inhibitor platform with VRDN-003 and VRDN-006 in development.
About
Viridian Therapeutics is a Greenwood Village, Colorado-based clinical-stage biotechnology company — backed by Y Combinator (W20) and publicly traded on NASDAQ (VRDN) — developing FcRn inhibitor therapies for thyroid eye disease (TED) and other serious rare diseases driven by IgG autoantibodies. Maintaining $636.6 million in cash and short-term investments as of March 2025 (sufficient to fund operations into the second half of 2027), Viridian is advancing veligrotug (subcutaneous FcRn inhibitor, BLA submission expected H2 2025 for TED, MAA to EMA expected H1 2026), VRDN-003 (topline clinical data expected H1 2026), and VRDN-006 (proof-of-concept data expected Q3 2025), with $86.6 million in R&D expenses in Q2 2025 reflecting accelerated clinical development investment.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.